J&J Shares Slip as Investors Assess Loss From Talc Legal Saga

The transcript discusses a $4.7 billion verdict against Johnson & Johnson due to claims that their talc products caused ovarian cancer. Despite the verdict, the company's financial health appears strong, with rising free cash flow and diversified revenue streams, particularly from pharmaceuticals. The consumer health division, affected by the lawsuit, now constitutes a smaller portion of total revenue. Analysts believe the company can withstand the financial impact, with many claims likely to be appealed or reduced.

What was the financial impact of the $4.7 billion verdict on Johnson & Johnson's shares?

• Shares rose by 1%

• Shares fell by 1%

• Shares remained stable

• Shares fell by 5%

How many claims are still outstanding against Johnson & Johnson?

• 11000 claims

• 9000 claims

• 7000 claims

• 5000 claims

What is one measure used to assess Johnson & Johnson's ability to handle the financial impact of the claims?

• Free cash flow

• Debt ratio

• Market share

• Net profit

What percentage of Johnson & Johnson's revenue does the consumer health division currently make up?

• More than 30%

• Less than 18%

• 25%

• 50%

Which sector has Johnson & Johnson focused on to offset the impact of the lawsuit?

• Pharmaceuticals

• Real estate

• Consumer electronics

• Automobiles